the effect of the new antiarrhythmic drug flecainide was examined in a controlled long-term study ( 1 to 44 months [ x = 17.7 +/- 12.4 ] ) in 36 patients , aged 18 to 76 years ( x = 44 +/- 16.3 ) , suffering from ventricular arrhythmias .
C0003195
antiarrhythmic
C0016229
flecainide